Form 4: IGM Biosciences Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Mary Beth Harler, Head of Research & Autoimmunity at IGM Biosciences, sold 1,487 shares of common stock to cover tax withholding obligations.
Summary
- On September 13, 2024, Mary Beth Harler, Head of Research & Autoimmunity at IGM Biosciences, sold 1,487 shares of IGM Biosciences common stock.
- The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units.
- The shares were sold at a weighted average price of $11.5388, with individual trades ranging from $11.20 to $11.795.
- Following the transaction, Harler directly owns 163,740 shares of IGM Biosciences common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to an executive's stock sale for tax purposes. It doesn't inherently convey positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are a routine part of the US stock market and are required by the SEC to provide transparency into the transactions of company insiders. They do not necessarily reflect the company's performance or future prospects.
Key Dates
| Date | Description |
|---|---|
| 09/13/2024 | Date of stock sale transaction. |
| 09/17/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.